• People
  • Practices
  • COVID-19 Resources
  • Insights
    • Firm News
    • Press Releases
    • Publications
    • Webcasts
    • Podcasts
    • Subscribe
    • Media Contacts
  • Careers
    • Career Opportunities
    • Attorney Development
    • Contact Us
  • About
    • Our Story
    • Awards & Accolades
    • Offices
    • Diversity
    • Pro Bono
    • Alumni
    • Contact Us
  • Search
  • Biography
  • Education
  • Recent Publications
Profile Picture

John D. W. Partridge

John
Partridge

Partner

CONTACT INFO

jpartridge@gibsondunn.com

TEL:+1 303.298.5931

FAX:+1 303.313.2857

Denver

1801 California Street, Suite 4200, Denver, CO 80202-2642 USA

  • Print
  • |
  • Share
  • |
  • vCard

PRACTICE

White Collar Defense and Investigations Administrative Law and Regulatory Practice Anti-Corruption & FCPA Class Actions Crisis Management FDA and Health Care False Claims Act/Qui Tam Defense Life Sciences Litigation Securities Enforcement Transnational Litigation

BIOGRAPHY

John Partridge, a Co-Chair of Gibson Dunn’s FDA and Health Care Practice Group and Chambers-ranked white collar defense and government investigations lawyer, focuses on government and internal investigations, white collar defense, and complex litigation for clients in the life science and health care industries, among others.  Mr. Partridge has particular experience with the Anti-Kickback Statute, the False Claims Act, the Foreign Corrupt Practices Act, and the Federal Food, Drug, and Cosmetic Act, including defending major corporations in investigations pursued by the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC).  In its 2020 rankings, Chambers & Partners reported that Mr. Partridge’s clients regard him as a “smart and strategic tactician.”

Health Care Fraud and Abuse Matters.  Mr. Partridge has represented clients in criminal and civil enforcement actions relating to alleged health care fraud and abuse, including actions conducted by DOJ, the U.S. Food and Drug Administration’s Office of Criminal Investigations, the Department of Health and Human Services Office of Inspector General, and State Attorneys General.  His substantive experience includes cases involving allegations relating to, among other things, advisory boards, clinical trials, compounding pharmacies, consultancy and speaker programs, electronic health record technology, free-of-charge goods and sampling, grants and IITs, importation of regulated products, off-label promotion, proctoring, product defects (and associated regulatory issues), product support activities, specialty pharmacies, and telehealth/telemedicine providers.

Among other current matters, Mr. Partridge is leading the defense of a multinational medical device company in an Anti-Kickback Statute-premised False Claims Act investigation relating to reimbursement support and marketing efforts, as well as a pharmaceutical company in a False Claims Act case based on purported fraud on the U.S. Patent and Trademark Office.  In recent years, he persuaded DOJ not to intervene in a wide-ranging FCA case involving alleged violations of the Anti-Kickback Statute and Federal Food, Drug, and Cosmetic Act by a global pharmaceutical company (in connection with a buy-and-bill drug); the relators voluntarily dismissed the action.

Along with colleagues at Gibson Dunn, Mr. Partridge wrote the criminal enforcement and pharmaceutical sampling chapters of PLI’s Pharmaceutical Compliance and Enforcement Answer Book 2019.  In 2018, LMG named Mr. Partridge “Best in Life Sciences” among its Americas Rising Stars.

FCPA and International Anti-Corruption Matters.  Mr. Partridge has handled a range of internal and government investigations focusing on potential violations of the FCPA.  Among other engagements, he recently defended a multinational medical device and pharmaceutical company in parallel DOJ and SEC securities fraud and FCPA investigations relating to the company’s activities in more than a dozen countries in Asia.  Previously, he served as a member of an international team of Gibson Dunn lawyers assisting the compliance monitor appointed in connection with one of the largest FCPA settlements to date (Siemens AG).  His compliance monitoring and investigations work has included activities in more than a dozen countries in Africa, Asia, Europe, and South America.

Compliance Counseling Matters.  In addition to advising multiple publicly traded corporations on investigations and litigation relating to potential healthcare fraud and abuse and FCPA issues, Mr. Partridge regularly counsels clients on the structure and effectiveness of their anti-corruption and anti-fraud compliance programs.

Experience.  Among other government investigation engagements, Mr. Partridge has counseled clients on:

  • An FCPA investigation relating to a medical device company’s relationships with health care providers, public hospitals, and third-party distributors in multiple countries in Asia;
  • An FCPA investigation relating to payment irregularities in Latin America;
  • FCPA investigations relating to a client’s business activities in Russia and the Middle East;
  • A False Claims Act investigation involving an electronic health records company’s interactions with physicians and certifications of its technology;
  • A False Claims Act investigation involving a medical device company’s alleged off-label promotion of one of its devices, as well as Anti-Kickback Statute issues and purported efforts to deceive FDA with regard to the severity of a design issue impacting the efficacy of the company’s product;
  • A False Claims Act investigation involving a pharmaceutical company’s sampling and pricing practices;
  • A False Claims Act investigation involving a Fortune 500 hospital management company (stemming from an extensive national investigation);
  • A grand jury investigation focusing on a former customer of Mr. Partridge’s client, a medical device company;
  • An SEC investigation relating to the accounting and disclosures of a for-profit education company; and
  • An SEC investigation focusing on the work of the independent auditors of a company that allegedly engaged in accounting fraud.

Mr. Partridge also has represented clients in a variety of matters before state and federal courts and at the trial and appellate levels.  Among other civil litigation matters, Mr. Partridge has represented:

  • A dietary supplement company in putative class actions relating to product labeling issues that raised questions relating to the Federal Food, Drug, and Cosmetic Act;
  • A pharmaceutical company in a False Claims Act case in federal court based on alleged fraud on the U.S. Patent and Trademark Office and purported product pricing issues tied to the patents at issue;
  • A pharmaceutical company in a False Claims Act case in federal court based on alleged violations of the Anti-Kickback Statute tied to sampling practices;
  • A medical device manufacturer in a case involving alleged violations of, among other laws, California’s Unfair Competition Law and False Advertising Law.  Mr. Partridge persuaded a California state court to sustain demurrers without leave to amend on federal preemption grounds.
  • A pharmaceutical company in a False Claims Act case in federal court based on purported violations of the Anti-Kickback Statute relating to product-support services, educational grants, and speaker events;
  • A large energy company in multiple federal court civil actions aimed at exposing and preventing enforcement of a fraudulently obtained, multi-billion dollar foreign judgment; and
  • A retailer of home improvement and construction products in a series of administrative and trial-level matters in states across the country where the retailer was denied refunds of sales tax payments (including in two trials in state court).

Mr. Partridge also has appellate experience.  In addition to appeals associated with certain cases listed above, his appellate matters include:

  • Open Door Ministries v. Lipschuetz, No. 14-SC-787 (Colo. 2016), in which Mr. Partridge persuaded the Colorado Supreme Court to reject an intervenor’s argument that a faith-based ministry’s promissory estoppel case against the City and County of Denver was barred by the Colorado Governmental Immunities Act.
  • Clyma v. Sunoco, Inc., 594 F.3d 777 (10th Cir. 2010), in which the U.S. Court of Appeals for the Tenth Circuit appointed Mr. Partridge as amicus curiae to brief the court on jurisdictional and First Amendment issues raised by a non-party’s appeal.

While seconded to the Denver City Attorney Office’s Prosecution and Code Enforcement Section, Mr. Partridge tried more than twenty criminal cases to juries or the court.

Education and Clerkship.  Mr. Partridge received his J.D., with distinction, from Stanford Law School in 2007.  While there, he served as an Executive Editor of the Stanford Law Review and was awarded the Law Review’s Board of Editors’ Award.  Mr. Partridge graduated magna cum laude and Phi Beta Kappa from Dartmouth College in 2002 with a B.A. in History and Psychology.  Before joining Gibson Dunn, Mr. Partridge clerked for the Honorable David M. Ebel of the United States Court of Appeals for the Tenth Circuit from 2007 to 2008.

Committees and Community Involvement.  Mr. Partridge serves as a member of Gibson Dunn’s Pro Bono, Professional Development, and Hiring Committees—and as the Hiring Partner for Gibson Dunn’s Denver office.  He also is a member of the Board of Trustees of the Legal Aid Foundation of Colorado, a non-profit dedicated to supporting access to justice for low-income residents of Colorado.  In recognition of his community involvement and professional achievements, he was recognized by the Denver Business Journal as a “40 Under 40” winner in 2019.

Admissions.  Mr. Partridge is admitted to practice law in the states of California and Colorado, as well as in the U.S. Courts of Appeal for the Eighth and Tenth Circuits, the U.S. District Courts for the District of Colorado, the Central District of California, and the Northern District of California.

 

EDUCATION

Stanford University - 2007 Juris Doctor

Dartmouth College - 2002 Bachelor of Arts

ADMISSIONS

California Bar

Colorado Bar

RECENT PUBLICATIONS

Firm News - February 10, 2022 | Nine Partners Named 2022 BTI Client Service All-Stars
Client Alert - February 3, 2022 | 2021 Year-End False Claims Act Update
Article - January 24, 2022 | Safe Harbors (and Other Strategies) for Life Sciences and Healthcare Companies in the International Anti-Corruption Storm
Client Alert - December 13, 2021 | U.S. Strategy on Countering Corruption Signals Focus on Enforcement
Webcasts - October 19, 2021 | Webcast: The False Claims Act – 2021 Update for Drug & Device Manufacturers
Client Alert - July 26, 2021 | 2021 Mid-Year False Claims Act Update
Client Alert - June 17, 2021 | China Constricts Sharing of In-Country Corporate and Personal Data Through New Legislation
Webcasts - May 25, 2021 | Webcast: Private Equity: Government Enforcement Trends – Parts 1 and 2
Webcasts - February 4, 2021 | Webcast: White Collar Enforcement Outlook 2021 – Sanctions/Export Controls, AML and Healthcare Fraud
Client Alert - January 27, 2021 | 2020 Year-End False Claims Act Update
Webcasts - October 22, 2020 | Webcast: The False Claims Act: Updates for Drug & Device Manufacturers
Client Alert - July 17, 2020 | 2020 Mid-Year False Claims Act Update
Client Alert - April 13, 2020 | FDA Round-Up: Overview of Emergency Actions to Expedite the Availability of Medical Products to Combat COVID-19
Client Alert - April 8, 2020 | Fraud in the COVID-19 Age: Examining and Anticipating Changing Enforcement Activity
Client Alert - March 31, 2020 | Implications of COVID-19 Crisis for False Claims Act Compliance
Client Alert - January 31, 2020 | 2019 Year-End False Claims Act Update
Webcasts - October 15, 2019 | Webcast: The False Claims Act – 2019 Mid-Year Update: Health Care and Life Sciences Sector
Client Alert - August 14, 2019 | 2019 Mid-Year FDA and Health Care Compliance and Enforcement Update – Providers
Client Alert - July 16, 2019 | 2019 Mid-Year False Claims Act Update
Client Alert - May 14, 2019 | Cooperation Credit in False Claims Act Cases: Opportunities and Limitations in DOJ’s New Guidance
Firm News - March 8, 2019 | John Partridge Named to Denver Business Journal’s 40 Under 40
Client Alert - March 7, 2019 | 2018 Year-End FDA and Health Care Compliance and Enforcement Update – Providers
Client Alert - February 12, 2019 | 2018 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 9, 2019 | 2018 Year-End False Claims Act Update
Publications - January 3, 2019 | FCPA Liability for Third-Party Conduct: Identifying Pitfalls and Minimizing Risk
Firm News - September 27, 2018 | Three Gibson Dunn Partners Recognized Among Americas Rising Stars
Webcasts - August 29, 2018 | Webcast: The False Claims Act – 2018 Mid-Year Update: Three Industry-Specific Programs
Webcasts - August 22, 2018 | Webcast: The False Claims Act – 2018 Mid-Year Update: Drug and Device Industries
Client Alert - July 26, 2018 | 2018 Mid-Year FDA and Health Care Compliance and Enforcement Update – Providers
Client Alert - July 11, 2018 | 2018 Mid-Year False Claims Act Update
Client Alert - February 6, 2018 | DOJ Policy Statements Signal Changes in False Claims Act Enforcement
Client Alert - January 23, 2018 | 2017 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 5, 2018 | 2017 Year-End False Claims Act Update
Article - November 17, 2017 | Potential FCPA Liability for Third-Party Conduct
Client Alert - September 4, 2017 | 2017 Mid-Year FDA and Health Care Compliance and Enforcement Update – Providers
Client Alert - August 25, 2017 | 2017 Mid-Year FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Webcasts - August 2, 2017 | Webcast: 2017 Mid-Year Update: The False Claims Act and Drug and Device Manufacturers
Client Alert - July 12, 2017 | 2017 Mid-Year False Claims Act Update
Client Alert - February 15, 2017 | 2016 Year-End Health Care Compliance and Enforcement Update – Providers
Client Alert - January 12, 2017 | 2016 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 5, 2017 | 2016 Year-End False Claims Act Update
Article - October 27, 2016 | FCA Liability after Escobar: Challenges and Opportunities for Device Companies
Webcasts - September 22, 2016 | Webcast: Hot Topics in Fraud and Abuse Enforcement Involving Health Care Providers
Client Alert - August 2, 2016 | 2016 Mid-Year Health Care Compliance and Enforcement Update – Providers
Article - August 1, 2016 | Evaluating U.S. Fraud and Abuse Compliance Controls, Including Corporate Integrity Agreement Provisions, for a Global Anti-Corruption Compliance Program
Client Alert - July 27, 2016 | 2016 Mid-Year FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - July 7, 2016 | 2016 Mid-Year False Claims Act Update
Client Alert - July 5, 2016 | 2016 Mid-Year FCPA Update
Client Alert - February 18, 2016 | 2015 Year-End Health Care Compliance and Enforcement Update – Providers
Client Alert - January 19, 2016 | 2015 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 6, 2016 | 2015 Year-End False Claims Act Update
Client Alert - January 4, 2016 | 2015 Year-End FCPA Update
Article - December 31, 2015 | Expanded Enforcement of Federal False Claims Act, RICO, and Antitrust Law Changes the Legal Landscape for Healthcare Providers
Article - October 7, 2015 | Tech Firms Targeted Under False Claims Act
Client Alert - August 13, 2015 | Another Successful Challenge to Restrictions on Off-Label Promotion
Article - August 3, 2015 | RICO Suits Challenge Off-Label Drug Marketing
Client Alert - July 16, 2015 | 2015 Mid-Year FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - July 8, 2015 | 2015 Mid-Year False Claims Act Update
Client Alert - July 6, 2015 | 2015 Mid-Year FCPA Update
Client Alert - January 14, 2015 | 2014 Year-End Health Care Compliance and Enforcement Update – Providers
Client Alert - January 14, 2015 | 2014 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 7, 2015 | 2014 Year-End False Claims Act Update
Client Alert - January 5, 2015 | 2014 Year-End FCPA Update
Client Alert - July 9, 2014 | 2014 Mid-Year False Claims Act Update
Client Alert - July 7, 2014 | 2014 Mid-Year FCPA Update
Client Alert - January 6, 2014 | 2013 Year-End FCPA Update
Client Alert - July 8, 2013 | 2013 Mid-Year FCPA Update
Client Alert - March 4, 2013 | In-House Search Warrant Checklist
Client Alert - January 8, 2013 | 2012 Year-End False Claims Act Update
Client Alert - January 2, 2013 | 2012 Year-End FCPA Update
Client Alert - December 4, 2012 | The End of Off-Label Prosecutions? The Second Circuit Rules That a Pharmaceutical Sales Representative’s Criminal Conviction for Off-Label Promotion Violates the First Amendment
Client Alert - November 19, 2012 | Decoding FCPA Enforcement: The U.S. Government Issues Comprehensive Guidance on the Foreign Corrupt Practices Act
Client Alert - July 11, 2011 | 2011 Mid-Year FCPA Update
Client Alert - November 16, 2010 | Do Rankings Matter? Transparency International Issues Its 2010 Corruption Perceptions Index
  • Sitemap
  • Client Extranet
  • Legal Notices
  • Modern Slavery Statement
  • Privacy Policy
  • Cookie Notice
  • Contact Us
©Gibson, Dunn & Crutcher LLP 2022. All rights reserved.
Top
This website uses cookies to provide analytics on user traffic. By continuing to browse our website, you consent to our use of cookies as set forth in our Cookie Policy. However you may visit Cookie Settings to customize your consent.
Cookie SettingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Analytics

Cookies that tie into analytics systems, such as Google Analytics, YouTube and Vimeo analytics for embedded video, etc. The following are the cookies installed by the service: _ga, _gid, collect, vuid

Performance

These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is aggregated and therefore anonymous. It is only used to improve how a website works. The following cookie is installed by the Google Analytics service: _gat

Save & Accept